Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 87 | 0.85 |
| pathways Reactome | 1 pathway; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 8637
Sealed predictions
- ACAD9 in dopamine neurons, braak-0.12 (p 0.767) → -0.33 (p 0.387)receipt 8644
Swarm cases
receipt 8644: ACAD9 in dopamine neurons, braak
- power
- full sample -0.31 (p 0.214, n 18), 95% CI -0.68 to +0.19. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.28 (p 0.254, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.25 (p 0.319, n 18). could be the mix.
- skeptic
- leave-one-out range -0.47 to -0.22, sign flips 0; without severely affected donors -0.31 (p 0.214, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.61 (p 0.0075, n 18) vs -0.31 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ACAD9 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ACAD9 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.38 p 0.183 (needs p < 2.5e-4)
Receipts
loading the receipts